Sinopharm Modern's Tacrolimus Ointment Wins NMPA Drug Registration Certificate
On September 18, 2026, Sinopharm Modern (600420) announced that the company had received a Drug Registration Certificate for tacrolimus ointment approved and issued by China's National Medical Products Administration. The certificate covers the ointment's use in the treatment of moderate to severe atopic dermatitis.
Why this event matters
The event has a measured impact on 1 industry. The strongest current signal is positive for Pharmaceuticals, with intensity 40/100 and 75% confidence over a medium term horizon.
Impact figures are analytical estimates that combine direction, intensity, confidence and event importance. They are not investment advice.